8329 Shenzhen Neptunus Interlong Bio-Technique Co. Ltd.
Shenzhen Neptunus Interlong Bio-Technique Co. (8329) news
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 8329, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Shenzhen Neptunus Interlong Bio-Technique Co. news
We have not published a story on Shenzhen Neptunus Interlong Bio-Technique Co. yet. When there is news, it will appear here.
Questions about Shenzhen Neptunus Interlong Bio-Technique Co.
What is the ticker symbol of Shenzhen Neptunus Interlong Bio-Technique Co.?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. trades under the ticker 8329 on HKEX.
Where is Shenzhen Neptunus Interlong Bio-Technique Co. listed?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. is listed on HKEX.
Which country or territory is Shenzhen Neptunus Interlong Bio-Technique Co. listed under?
Our directory records Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. under Hong Kong.
What does Shenzhen Neptunus Interlong Bio-Technique Co. do?
Our directory classifies Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Shenzhen Neptunus Interlong Bio-Technique Co.?
The ISIN recorded for Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. is CNE100000775.
Does aibio.space cover Shenzhen Neptunus Interlong Bio-Technique Co.?
aibio.space lists Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Which companies are similar to Shenzhen Neptunus Interlong Bio-Technique Co.?
Companies in our directory listed in the same country and business area as Shenzhen Neptunus Interlong Bio-Technique Co.: Regencell Bioscience Holdings, China Traditional Chinese Medicine Holdings Co., InSilico Medicine Cayman TopCo, SSY Group, China Resources Pharmaceutical Group, Sanai Health Industry Group Company.
Investor discussion: Shenzhen Neptunus Interlong Bio-Technique Co.
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Press releases
- HKEXnews
VOLUNTARY ANNOUNCEMENT - ENTERING INTO OF JOINT VENTURE AGREEMENT
- HKEXnews
VOLUNTARY ANNOUNCEMENT - RECEIPT OF REGULATORY DECISION LETTER BY THE CONTROLLING SHAREHOLDER
- HKEXnews
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
- HKEXnews
INSIDE INFORMATION ANNOUNCEMENT SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PROFIT WARNING
- HKEXnews
INSIDE INFORMATION ANNOUNCEMENT - SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PROFIT WARNING
- HKEXnews
- HKEXnews
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 23 DECEMBER 2025
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
CONTINUING CONNECTED TRANSACTION - RENEWAL OF NEPTUNUS GROUP SALES FRAMEWORK AGREEMENT
Stock chart
Listing details
- Company
- Shenzhen Neptunus Interlong Bio-Technique Co. Ltd.
- Ticker
- 8329
- Listing
- HKEX
- Country or territory
- Hong Kong
- Business scope
- Pharmaceuticals: Major
- ISIN
- CNE100000775
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio